RVTY · Revvity, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted operating profit margin non-GAAP | 23.6% | Q1 2026 | — |
| Diagnostics adjusted operating profit margin non-GAAP | 21.8% | Q1 2026 | — |
| Diagnostics organic revenue growth | 4% | Q1 2026 | — |
| Diagnostics pro forma organic revenue growth | 9% | Q1 2026 | — |
| Life Sciences adjusted operating profit margin non-GAAP | 28.7% | Q1 2026 | — |
| Life Sciences organic revenue growth | 3% | Q1 2026 | — |
| Organic revenue growth | 3% | Q1 2026 | — |
| Pro forma organic revenue growth | 6% | Q1 2026 | — |
| Organic revenue growth from continuing operations | 4% | Q4 FY2025 | — |
| Reported revenue growth from continuing operations | 6% | Q4 FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVTY
this stock
Revvity, Inc.
|
$12.78B | +17.6% | -13.5% | 54.8 | 6.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.80B | +1.7% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -7.6% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$45.29B | +36.1% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -18.2% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVTY | -1.7% | +2.9% | +16.6% | +1.1% | +17.6% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | -1.3% | +0.4% | +5.9% | -1.6% | +5.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.